REPLIGEN CORP (RGEN) stock intrinsic value fair value estimate & owner earnings analysis

Repligen sells the filters, chromatography columns and analytical instruments that biologic-drug makers use in manufacturing, plus the Protein A ligands used to purify antibodies. Most revenue is single-use consumables written into a customer's validated production process, so they are re-ordered for as long as the drug is made. No customer was 10% or more of revenue in 2023, 2024 or 2025. Revenue was $738 million in 2025 (49% North America, 34% Europe, 17% Asia Pacific and rest of world). What the business really earns. We measure the cash the operating business produces for its owners: operating cash flow, minus the stock handed to employees (a real cost, about $33 million in 2025), minus the part of capital spending needed just to stay in business, with the year-to-year swings in inventory and receivables removed and the rent on leased sites left in as the cost it is. We leave out the roughly $28 million a year of interest earned on the company's cash pile, because that cash is counted separately below. On that basis the business produced about $2.26 a share in 2022 (the COVID-era peak), $0.65 in 2023 and $0.05 in 2024 (customers destocking; 2024 also carries a one-time $22 million stock award, without which it was about $0.45), and $1.44 in 2025. The 2022-2025 cycle puts the through-cycle level near $1.04. The downturn was real: revenue fell 21% in 2023 and was flat in 2024, and cash earning power fell by more than 80% from peak to trough. The last three half-years run at roughly $1.6 to $1.9 a share annualized (revenue up 13% in the first half of 2026, gross margin near 54%); these run-rates are approximations built from interim filings. Because the recovery is corroborated across several periods, the base case uses $1.50 a share. Cash earnings went from about $0.45 to $1.44 in the latest full year; our first year is only about 4% above 2025, so no reversal of a slowdown is being assumed. What we credited and left out. We credited no growth beyond returning to the level already reached. Market expansion, share gains, new cell-therapy products, margin expansion and management's synergy targets are not contracted and not a proven self-funded routine, so they are worth nothing here. The company carries heavy intangible amortization from many acquisitions and has bought businesses steadily with shares, convertible debt and cash (about $312 million of acquisitions in 2023-2025), so rather than assume its products last forever we fade earnings by 3% a year after year ten in the base case. The BioLife deal. On October 6, 2026 Repligen completed its roughly $1.5 billion purchase of BioLife Solutions: $11.25 in cash plus 0.1442 Repligen shares per BioLife share. We estimate about $575 million of cash paid, about 7.4 million new Repligen shares (diluted shares rising from about 56.7 million to about 64 million) and about $115 million of BioLife cash acquired; final figures are not yet in a filing. BioLife makes cell-therapy preservation media with $96 million of 2025 revenue (growing 20%+ in 2026), but after counting its stock compensation it has had negative owner cash flow in nine of the last ten years. That record does not yet support the price, so the base and bear cases credit its operating business with nothing. The bull case credits about $13 million a year, roughly its cash flow if its stock compensation fell to Repligen's level. This is the largest change since our previous analysis, which was made on a different basis and is not comparable. Debt. Repligen owes $600 million of 1.00% convertible notes due December 15, 2028 (conversion price $203.06). Because the coupon is far below market we count them at about $540 million. After the BioLife payment, cash and securities are about $350 million, so the 2028 maturity will need operating cash, conversion or refinancing; the bear case charges for it. Cases (per share, about 64 million shares). Bear $4.40: a repeat of the 2023-2024 destocking starts immediately (cash earnings of $0.65, then $0.45, then $0.85) and the business then settles at the $1.04 through-cycle level, fading 5% a year after year ten. The business is worth about $658 million, plus $165 million of spare cash (after $100 million of further acquisitions that return nothing and $25 million of costlier refinancing), minus $540 million of debt, leaving about $283 million. Base $13.90: $1.50 a share held flat, then fading 3% a year. The business is worth about $1,137 million, plus $290 million of spare cash, minus $540 million of debt, leaving about $887 million. Bull $27.00: recovery to $1.90, $2.15 and then $2.26 (the 2022 level) on production capacity Repligen already built with $152 million of capital spending in 2021-2022, fading 2% a year after year ten, plus about $185 million for BioLife. The business is worth about $1,979 million, plus $290 million of cash, minus $540 million of debt, leaving about $1,729 million. How we reached the margin-of-safety price of $7.50. We are fairly sure the recovery to $1.4-$1.9 a share is real because several half-years confirm it, but not sure it persists: the same business earned $0.05 a share two years earlier. The worst plausible outcome is another destock arriving while Repligen owes $600 million in 2028 against about $350 million of cash and a large new acquisition still to be digested; the business would survive because it has no customer concentration and sells consumables embedded in approved processes, but shareholders would be worth little more than the bear case. If we are wrong about the three things most likely to be wrong, BioLife's value (nothing versus $185 million), the margin level ($1.04 versus $2.26) and the timing of the next downturn, the shares range from about $4 to $27. The price assumes a holding period of four to five years for value to show. The company pays no dividend, but it retains roughly $1.2 to $1.3 a share each year, which accumulates inside the business, and five years of that equals most of the $7.50 margin-of-safety price in cash. The price is set no higher because it leaves room for the bear outcome while the base case, if it simply holds, still implies a 20% annual return. What would prove this wrong: BioLife turning cash-positive faster than its record suggests, or cash earnings settling permanently near 2025's $1.44 rather than fading, would raise value; a second destock or a hard refinancing would lower it.